ArticleHuman vaccines & immunotherapeutics2019

Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old.

Desirée Van Oorschot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.